Mutations in CYC1, Encoding Cytochrome c1 Subunit of Respiratory Chain Complex III, Cause Insulin-Responsive Hyperglycemia  by Gaignard, Pauline et al.
REPORT
Mutations in CYC1, Encoding Cytochrome c1
Subunit of Respiratory Chain Complex III,
Cause Insulin-Responsive Hyperglycemia
Pauline Gaignard,1,21 Minal Menezes,2,21 Manuel Schiff,3,4,5 Aure´lien Bayot,3,4 Malgorzata Rak,3,4
He´le`ne Ogier de Baulny,5 Chen-Hsien Su,6 Mylene Gilleron,7,8 Anne Lombes,7,8 Heni Abida,6
Alexander Tzagoloff,6 Lisa Riley,9 Sandra T. Cooper,2,10 Kym Mina,11,12 Padma Sivadorai,13
Mark R. Davis,13 Richard J.N. Allcock,14,15 Nina Kresoje,14 Nigel G. Laing,16,17 David R. Thorburn,18,19
Abdelhamid Slama,1 John Christodoulou,2,9,20 and Pierre Rustin3,4,*
Many individuals with abnormalities of mitochondrial respiratory chain complex III remain genetically undefined. Here, we report
mutations (c.288G>T [p.Trp96Cys] and c.643C>T [p.Leu215Phe]) in CYC1, encoding the cytochrome c1 subunit of complex III, in
two unrelated children presenting with recurrent episodes of ketoacidosis and insulin-responsive hyperglycemia. Cytochrome c1, the
heme-containing component of complex III, mediates the transfer of electrons from the Rieske iron-sulfur protein to cytochrome
c. Cytochrome c1 is present at reduced levels in the skeletal muscle and skin fibroblasts of affected individuals. Moreover, studies on yeast
mutants and affected individuals’ fibroblasts have shown that exogenous expression of wild-type CYC1 rescues complex III activity,
demonstrating the deleterious effect of each mutation on cytochrome c1 stability and complex III activity.Complex III (CIII) of the mitochondrial respiratory chain
contains 11 subunits, one of which (cytochrome b) is
encoded by mitochondrial DNA. CIII conveys electrons
from ubiquinol to cytochrome c. It associates with com-
plexes I (CI) and IV (CIV) to form the respirasome.1 Cyto-
chrome c1 (Cyt c1), cytochrome b, and the Rieske protein
are the three CIII redox components. The heme moiety
of Cyt c1 is in the N-terminal domain, located in the inter-
membrane space, where it accepts electrons from the
Rieske protein. Cyt c1 is anchored to the phospholipid
bilayer by a single C-proximal transmembrane segment.2
Primary CIII deficiencies, although infrequent, have
strikingly different clinical presentations. Mutations in
mitochondrial CYTB or in the nuclear genes encoding
CIII subunits or assembly factors elicit a wide range of
tissue-specific defects in affected individuals; they include
encephalopathy with renal involvement or lethal infantile
hepatic failure (from BCS1L [MIM 124000] mutations in
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sis, and ataxia (from UQCRQ [MIM 615159] mutations);5
mitochondrial encephalopathy (from BCS1L, TTC19
[MIM 613814], CYTB [MIM 516020] mutations);6 pili torti
and sensorineural hearing loss, known as Bjo¨rnstad
syndrome (from BCS1L mutations);7 optic neuropathy,
exercise intolerance, and/or cardiomyopathy (from CYTB
mutations);8 and transient episodes of hypoglycemia and
lactic acidosis (from UQCRB [MIM 191330] and UQCRC2
[MIM 191329] mutations).9,10
We first carried out respiratory chain (RC) enzyme
analysis of muscle, liver, and fibroblasts of two children
(from unrelated consanguineous families) presenting
with unexplained ketoacidosis and recurrent hyperlactaci-
demia. All investigations were carried out according to the
recommendations of the relevant local ethical committees
and with the informed consent of affected individuals
and/or their families. The study revealed an isolated CIII
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Figure 1. Gene Analysis in Families Affected by CYC1 Mutations
(A) Pedigrees of the Lebanese (with P1) and Sri Lankan (with P2) families. Affected individuals (dark symbols) harbor homozygous (/)
mutations. Unaffected individuals are either heterozygous (/þ) or wild-type (þ/þ).
(B) Analysis of CYC1 genomic DNA. For P1, a single candidate disease-causing homozygous missense variant in CYC1 was identified by
exome sequencing. For P2, who has defective CIII activity, a candidate-gene strategy resulted in sequencing cDNA obtained from total
RNA of cultured fibroblasts and revealed a missense mutation (c.643C>T) in CYC1.
(C and D) Cyt c1 structures (C) and alignment (D).The first child (P1; II-3, Lebanese family in Figure 1) is
the son of first-cousin parents of Lebanese background.
An older brother has autism and intellectual disability,
and an older sister and a younger brother exhibit normal
growth and development. The proband was born at
36 weeks of gestation (Table S2) after a pregnancy compli-
cated by gestational diabetes, for which his mother needed
insulin therapy. His birth weight was 2,300 g (10–50th
percentile), his length was 46 cm (10–50th percentile),
and his head circumference was 32 cm (50–90th percen-
tile). He had normal early development. He first presented
at 5 months of age with severe metabolic ketoacidosis (pH
7.04) after a 24 hr history of a febrile illness causing
vomiting (Table S1). His initial blood lactate was
13 mmol/l (normal range ¼ 0.7–2.0 mmol/l), and he also
had hyperammonemia (260 mmol/l; normal range ¼ 10–
50 mmol/l). He was treated with fluid resuscitation, sodium
benzoate, and arginine, and over the next few days his
biochemistry corrected. He went on to have recurrentThe Amerepisodes of fulminant lactic acidemia with intercurrent
illnesses; his lactate-to-pyruvate ratio was as high as 66,
and his blood glucose was labile (it fluctuated from 3 to
30 mmol/l) and required insulin therapy. This prompted
us to investigate RC enzyme in muscle, liver, and skin
biopsies, which revealed a severe and consistent isolated
CIII defect (the ratio of CIII to citrate synthase activity
was 4%, 24,% and 25% of the mean control values in liver,
muscle, and skin fibroblasts, respectively) (Table S1). At
34 months of age, he was exhibiting normal development
and was assessed to have normal cardiac, ophthalmolog-
ical, and audiological functions. His weight was 11.2 kg
(first percentile), and his length was 86.5 cm (first percen-
tile). His head circumference 6 months earlier was 48.0 cm
(23rd percentile).
The second affected child (P2; II-3, Sri Lankan family in
Figure 1) is a girl (third child) born to first-cousin parents
of Sri Lankan background. After an uneventful pregnancy
and delivery, she presented with mild growth retardationican Journal of Human Genetics 93, 384–389, August 8, 2013 385
andcongenital leftptosis. Shewas admittedat2.5 yearsofof
age for acute vomiting with dehydration and progressive
neurological deterioration, which led to a coma. A
biological workup (Table S2) revealed hyperglycemic
ketoacidosis with hyperlactatemia, liver failure, and
hyperammonemia. The clinical condition rapidly im-
proved with intravenous rehydration and insulin. During
the following years, she exhibited normal psychomotor
development, moderate failure to thrive, and numerous
episodes of acute decompensation with ketoacidosis,
hypoglycemia or hyperglycemia, and liver failure with
hyperammonemia usually triggered by minor infections.
A metabolic workup performed when the child was not de-
compensated disclosedmild permanent hyperlactacidemia
(10 mmol/l; normal range ¼ 1.0–3.75 mmol/l) with an
increased lactate-to-pyruvate ratio (27 mmol/l; normal ¼
10–17 mmol/l), suggestive of a RC disorder. CIII deficiency
was detected inmuscle andwas confirmed in cultured fibro-
blasts (Table S1). At the last follow-up examination, P2 was
18 years of age and had normal development and
schooling. She still presents with rare episodes ofmetabolic
decompensation with lactic acidosis.
For P1, who has isolated CIII deficiency, BCS1L, UQCRB,
TTC19 (genes previously associated with CIII defects), and
UQCR10 (MIM 610843; encoding a subunit of CIII) were
sequenced, but no pathogenic mutations were identified.
Whole-exome sequencing was subsequently performed.
A library was first obtained fromDNA (3 mg) fragmentation
by sonication and ligation to SOLiDTM system sequencing
adaptors and was next enriched for exomic sequences with
the SeqCap EZ Human Exome Library v.2.0 exome-capture
system (Nimblegen, Roche Diagnostics). After sequencing
and alignment,>80% of the exome was covered at a depth
of 20-fold or greater (average depth ¼ 152-fold). Calling of
single-nucleotide variants (SNVs) and indels was per-
formed with LifeScope 2.5 (Life Technologies), and the
resulting variant calls (>25,000 SNVs and >3,500 indels)
were filtered with ANNOVAR 11 with in-house modifica-
tions. Genes were annotated with ENCODE Gencode
v.11 (October 2011 freeze, GRCh37).Variants were first
filtered against the 1000 Genomes database (2012 February
release), whereby variants with a minor allele frequency
greater than 0.5% were filtered out. Second, remaining
variants were filtered against the dbSNP135 common data-
base. The remaining variants were matched to a list of
nuclear mitochondrial genes, and in silico prediction using
Alamut v.2 (Interactive Biosoftware) identified variants of
potential interest in 21 mitochondrial genes. Variants
were filtered on the basis of recessive inheritance and a
predicted role in CIII deficiency. A single candidate
disease-causing homozygous missense variant in CYC1
(RefSeq accession number NM_001916.3) was identified:
c.288G>T (p.Trp96Cys) (Figure 1). Bidirectional Sanger
sequencing confirmed the variant in this individual and
demonstrated segregation of the variant within the family
(Figure 1). The mutation was absent in 81 unrelated
Lebanese controls.386 The American Journal of Human Genetics 93, 384–389, August 8For the Sri Lankan girl (P2), who has low CIII activity in
muscle and fibroblasts, the 11 genes coding for CIII
subunits were sequenced (ABI Prism 3130XL; Applied
Biosystems). DNA was extracted according to standard
procedure, and mitochondrial DNA was examined by
long-range PCR. Sequence analysis of CYTB and BCS1L
was performed on gDNA. Sequence analysis of the nine
nuclear genes (CYC1, UQCRFS1 [MIM 191327], UQCRC1
[MIM 191328], UQCRC2, UQCRH [MIM 613844], UQCRB,
UQCR10, UQCRQ, and UQCR [MIM 609711]) encoding
CIII subunits was performed on cDNA obtained from
total RNA of cultured fibroblasts. A missense mutation
(c.643C>T) resulting in a nonconservative substitution
(p.Leu215Phe) within a highly conserved region of Cyt c1
was detected in CYC1 (Figure 1). This mutation was found
to be heterozygous in each of her clinically unaffected
parents and absent from her two unaffected siblings. This
mutation is absent from dbSNP, 1000 Genomes databases,
and 100 sequenced control alleles.
Immunoblot analysis of fibroblasts and skeletal-muscle
samples from P1 and P2 showed a severe reduction in
Cyt c1 levels (<10% of control levels), suggesting that the
mutationsmake the Cyt c1 protein highly unstable (Figures
2A–2C and Figure S1). The reduction of Cyt c1 levels was
accompanied by markedly reduced levels of assembly-
dependent CIII subunits (core 2), especially in the muscle
(Figures 2A and 2B). The severe depletion of Cyt c1, core
2 (P1), and core 1 (P2) subunits accounts for the loss of
activity of the complex, which could hardly be assembled
in the absence of these subunits. For P1, reduced levels of
assembly-dependent subunits of CI (subunit NDUFB8)
was also observed in fibroblasts only (Figure 2A), suggest-
ing that CYC1 mutations might also affect the in vivo
stability or assembly of other RC components. Accord-
ingly, in P2 fibroblasts, the severe reduction of Cyt c1 and
core 1 was accompanied by the absence of RC supercom-
plexes (Figure 2C).
To confirm that the two CYC1 mutations were respon-
sible for the observed clinical and biochemical pheno-
types, we examined the effect of the mutations on
mitochondrial function in Saccharomyces cerevisiae. The
human mutations were engineered at orthologous
positions c.228G>T (p.Leu195Phe) and c.585G>T
(p.Trp76Cys) within the yeast gene (y-CYC1). The wild-
type and mutant genes were either introduced in multiple
copies on an episomal plasmid or integrated into the chro-
mosomal DNA at the URA3 locus of a respiratory-deficient
haploid strain carrying a null mutation in y-CYC1
(Dy-cyc1) Transformants confirmed to have a single copy
of the mutant genes failed to grow on nonfermentable
carbon sources (Figure 2D). In contrast, the growth defect
of the Dy-cyc1 mutant was rescued in transformants
harboring multiple copies of the mutant genes. As ex-
pected, the wild-type gene (either in single copy or mul-
tiple copies) restored wild-type growth on the respiratory
substrates. The CIII-dependent activities of mitochondria
from the different transformants were consistent with, 2013
Figure 2. Analysis of Cyt c1 Mutant Cells
and Rescue in Yeast Cells
(A–C) Immunoblots of affected indi-
viduals’ (P1 [with Cyt c1 p.Trp96Cys] and
P2 [with Cyt c1 p.Leu215Phe]) RCs
under denaturing (A and B) or native (C)
conditions.
(A and B) Immunoblot of the levels of Cyt
c1 oxidative-phosphoylation subunits in
fibroblasts and skeletal muscle (A and B).
Compared to those of the controls
(Ctrl1–Ctrl4), levels of Cyt c1 and CIII
were severely reduced in affected individ-
ual fibroblasts and skeletalmuscle. Second-
ary reductions of assembly-dependent
subunits of CI and CIV were also observed.
SDS-PAGE and immunoblot were carried
out on whole-cell lysate from fibroblasts
(20 mg) or skeletal-muscle homogenate
(5 mg). ‘‘1/4 ’’ indicates that
1/4 of the sample
was loaded.
(C) Protein extract from fibroblasts (6%
digitonin; 50 mg) was separated by blue-
native PAGE on a 3.5%–12% polyacryl-
amide gel. Proteins were transferred to a
polyvinylidene fluoride (PVDF) membrane
and probed with a set of antibodies as
indicated in the figure. The various super-
complexesandcomplexesand theATPsyn-
thase (F1F0) are identified in the margins.
(D) Growth of wild-type andmutant yeast.
Serial dilutions of the parental W303-1A
strain, the Dy-cyc1 null mutant, and the
null mutant harboring the wild-type (Dy-
cyc1/i-yCYC1) or mutant genes in a single
copy by integration at the URA3 locus (Dy-cyc1/i-y-cyc1) or in multiple copies in an episomal plasmid (Dy-cyc1/e-y-cyc1) were serially
diluted and spotted on plates supplemented with glucose or glycerol plus ethanol and incubated at 30C for 2 days.
(E) Immunoblot analysis of yeast Cyt c1. In the upper two panels, mitochondrial extracts (3% digitonin; 250 mg protein) were separated
by blue-native PAGE on a 4%–13% polyacrylamide gel. Proteins were transferred to a PVDF membrane and stained with Ponceau red
before being probed with a polyclonal antibody against yeast Cyt c1. The various supercomplexes and complexes and the ATP synthase
(F1F0) are identified in the margins. In the lower panel, mitochondrial proteins (37 mg) were separated by SDS-PAGE on a 15% polyacryl-
amide gel and transferred to nitrocellulose and probed with a polyclonal antibody against yeast Cyt c1.their growth phenotypes. Transformants with a single
copy of the mutant genes had only 7% of the activity
measured in the wild-type integrant (Table S3). The
NADH cytochrome c reductase activity of CI and CIII
increased to 52% and 33%, respectively, of that of the
wild-type when the mutant genes were introduced on a
multicopy plasmid.
Immunoblot analysis of yeast mitochondria revealed a
near-complete absence of Cyt c1 and CIII in mutants with
single copies of the p.Leu195Phe or p.Trp76Cys proteins
(Figure 2E), consistent with results in affected individuals’
fibroblasts and muscles (Figures 2A–2C). Even though the
levels of Cyt c1 in mutants overexpressing the genes were
similar or even higher than those in the wild-type, immu-
nochemically detectable CIII (as the dimer or as part of
supercomplexes) was significantly reduced and correlated
with their NADH cytochrome c reductase activities
(Figure 2E and Table S3). Overexpression of the wild-type
or mutant yeast gene led to some aggregation of Cyt c1,
which was not completely dissociated in the sample
buffer. Some overexpression of Cyt c1 was also evident in
the strain with an integrated copy of the wild-type gene,The Amerresulting in aggregation as well. Presumably, when inte-
grated at the URA3 locus, the mutant genes are also
expressed above wild-type levels but are readily degraded
as a result of their reduced stability. When expressed from
a multicopy plasmid, however, the turnover rate is insuffi-
cient to clear all of the aggregated Cyt c1.
Data obtained with the recombinant lentiviral con-
structs containing either wild-type or mutant CYC1
cDNA of affected individual fibroblasts mimicked the re-
sults obtained with yeast. Moderate overexpression of
wild-type, but not mutant, CYC1 (obtained with the use
of a standard number of virus particles; multiplicity of
infection [MOI] ¼ 5) in the context of the endogenous
c.643C>T mutant gene led to a partial rescue of CIII (see
P2 in Figures S2A and S2B). Increased expression of CYC1
achieved with virus-particle levels of MOI ¼ 120 allowed
even mutant CYC1 to partially rescue CIII (see P1 in
Figure S2C and S2D).
Together, the data obtained with cultured fibroblasts and
yeast establish the deleterious effect of two CYC1 muta-
tions for CIII assembly or stability in two individuals of
different ethnic backgrounds; these mutations lead toican Journal of Human Genetics 93, 384–389, August 8, 2013 387
quite a similar clinical presentation of ketoacidosis and lac-
tic acidosis associated with insulin responsive hyperglyce-
mia but with normal cognition. The mutations resulted in
reduced levels of Cyt c1 and CIII and appeared to primarily
affect the tertiary structure of Cyt c1 and thus render it
more susceptible to proteolysis or alternatively less effi-
cient to assembly with its partner subunits. Both circum-
stances would explain the low steady-state concentration
of altered Cyt c1 in the single-copy yeast integrants and
the partial rescue of CIII assembly when the genes are ex-
pressed from a multicopy plasmid. Analysis of the Cyt c1
crystal structure11 suggests that conformational changes
due to the amino acid substitutions (Figure 1C) are most
likely to occur in the extramembrane domain, whose func-
tion, though not clearly understood, plays a role in main-
taining the structural and functional integrity of CIII.2 The
tertiary-structure change might be a collapse of the long
random coil containing the inward-facing tryptophan
when the latter is replaced by the smaller cysteine or
when a bulkier phenylalanine is substituted for the
leucine, which is only 3.9A˚ away from a methyl group of
the heme moiety. Unexpectedly, the redox activity of the
altered proteins was retained in the transformants
harboring multiple copies of the gene (Table S3). This
was particularly surprising in the case of the p.Leu195Phe
substitution (modeling the human p.Leu215Phe substitu-
tion), which is expected to alter the heme environment.
These data suggest that the substitutions primarily affect
the structural integrity of Cyt c1 and thereby reduce its con-
centration and its likelihood to assemble with other CIII
subunits. The assembly defect can be compensated for by
an increase in the pool of available altered Cyt c1, either
in the yeast transformants harboring multiple copies of
the gene or in fibroblasts with a high MOI. Under these
conditions, the resultant CIII appears to be fully active in
transferring electrons to cytochrome c.
It is interesting to note that even though the RC assays
(Table S2) showed affected individuals to have mainly an
isolated CIII deficiency, the immunoblot data for fibro-
blasts revealed a severe reduction of supercomplexes. Simi-
larly, in the yeast complementation studies, there were
reduced levels of CIII dimers and supercomplexes. Previous
studies have suggested that it is essential to have a fully
assembled CIII for the stability and activity of CI12 and
that together, CI and CIII form a stable core respirasome
to which CIV can also bind.1 These data collectively
suggest that the CYC1 mutations affect the stability or
assembly of the respirasome, most likely as a result of
decreased CIII levels stemming from the depletion in Cyt
c1, core 1, and core 2 subunits.
CIII deficiencies have highly variable clinical presenta-
tions, although they have common defects in insulin-
signaling mechanisms and lactic acidosis (for example,
UQCRB and UQCR29,10). Mitochondrial oxidative activity
due to RC deficits can be considered one of the key deter-
minants underlying hyperglycemia.13 Studies have sug-
gested that CIII is one of the major sources of reactive388 The American Journal of Human Genetics 93, 384–389, August 8oxygen species (ROS).14 Given that ROS has been shown
to affect insulin signaling and action, this could explain
the hyperglycemia phenotype in the affected inviduals.15
In conclusion, our studies show that two different
CYC1 mutations cause ketoacidotic and lactic acidotic
encephalopathy and insulin-responsive hyperglycemia.
This clinical phenotype is the result of severe reductions
in cytochrome c1, as well as marked reductions in other
assembly-dependent CIII subunits. Rescue experiments
confirm the CYC1 mutations to be the primary cause of
CIII defects. The similarity of the clinical symptoms in
the two affected individuals leads us to recommend muta-
tion screening for CYC1 in young children presenting with
recurrent lactic acidosis and hyperglycemia.Supplemental Data
Supplemental Data include two figures and three tables and can be
found with this article at http://www.cell.com/AJHG.Acknowledgments
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